X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (65) 65
humans (63) 63
male (54) 54
female (53) 53
middle aged (46) 46
oncology (46) 46
aged (42) 42
hematology (41) 41
adult (38) 38
lymphomas (36) 36
cancer (32) 32
chemotherapy (30) 30
life sciences (30) 30
aged, 80 and over (29) 29
lymphoma (26) 26
treatment outcome (23) 23
antineoplastic combined chemotherapy protocols - therapeutic use (22) 22
rituximab (22) 22
[sdv.can]life sciences [q-bio]/cancer (20) 20
disease-free survival (17) 17
analysis (16) 16
b-cell lymphoma (16) 16
non-hodgkins-lymphoma (16) 16
prognosis (16) 16
young adult (16) 16
[ sdv.can ] life sciences [q-bio]/cancer (15) 15
retrospective studies (15) 15
adolescent (14) 14
follow-up studies (14) 14
transplantation (13) 13
elderly-patients (12) 12
hodgkin lymphoma (12) 12
neoplasm staging (12) 12
patients (12) 12
survival (12) 12
therapy (12) 12
antineoplastic agents - therapeutic use (11) 11
prospective studies (11) 11
response criteria (11) 11
survival analysis (11) 11
survival rate (11) 11
care and treatment (10) 10
follicular lymphoma (10) 10
hemic and lymphatic diseases (10) 10
lymphoma, large b-cell, diffuse - drug therapy (10) 10
lymphoma, large b-cell, diffuse - mortality (10) 10
medical research (10) 10
medicine, experimental (10) 10
primary cns lymphoma (10) 10
antineoplastic combined chemotherapy protocols - adverse effects (9) 9
disease (9) 9
hematology, oncology and palliative medicine (9) 9
hodgkin's disease (9) 9
lymphocytes b (9) 9
r-chop (9) 9
relapse (9) 9
stem cell transplantation (9) 9
toxicity (9) 9
antibodies, monoclonal, murine-derived - therapeutic use (8) 8
antineoplastic combined chemotherapy protocols - administration & dosage (8) 8
article (8) 8
clinical trials (8) 8
combined modality therapy (8) 8
expression (8) 8
recurrence (8) 8
risk (8) 8
stem cells (8) 8
autografts (7) 7
cyclophosphamide (7) 7
human health and pathology (7) 7
lymphoma, large b-cell, diffuse - pathology (7) 7
medicine & public health (7) 7
phase-ii (7) 7
central nervous system neoplasms - pathology (6) 6
central nervous system neoplasms - therapy (6) 6
clinical neurology (6) 6
doxorubicin - administration & dosage (6) 6
immunotherapy (6) 6
kaplan-meier estimate (6) 6
medical and health sciences (6) 6
medicin och hälsovetenskap (6) 6
original reports (6) 6
radiotherapy (6) 6
time factors (6) 6
transplantation, autologous (6) 6
trial (6) 6
[sdv]life sciences [q-bio] (5) 5
abridged index medicus (5) 5
antibodies, monoclonal, murine-derived - administration & dosage (5) 5
central nervous system (5) 5
cyclophosphamide - administration & dosage (5) 5
cyclophosphamide - therapeutic use (5) 5
cytarabine - administration & dosage (5) 5
disease progression (5) 5
dlbcl (5) 5
doxorubicin (5) 5
doxorubicin - adverse effects (5) 5
doxorubicin - therapeutic use (5) 5
drug administration schedule (5) 5
features (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10036, pp. 2402 - 2411
Summary Background Short intensive chemotherapy is the standard of care for adult patients with Burkitt's leukaemia or lymphoma. Findings from single-arm... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | CODOX-M/IVAC | CLEAVED-CELL LYMPHOMA | ACUTE-LYMPHOBLASTIC-LEUKEMIA | MULTIAGENT CHEMOTHERAPY | ADOLESCENTS | PLUS RITUXIMAB | NON-HODGKIN-LYMPHOMA | SURVIVAL RATE | PEDIATRIC-ONCOLOGY-SOCIETY | CHILDREN | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Injections, Intravenous | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Patient Selection | Burkitt Lymphoma - pathology | Hydrocortisone - administration & dosage | Vincristine - administration & dosage | Adult | Female | France | Odds Ratio | Burkitt Lymphoma - drug therapy | Doxorubicin - administration & dosage | Prednisone - administration & dosage | Drug Administration Schedule | Biomarkers, Tumor - analysis | Proportional Hazards Models | Treatment Outcome | Burkitt Lymphoma - diagnosis | Burkitt Lymphoma - chemistry | Cytarabine - administration & dosage | Rituximab - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Methotrexate - administration & dosage | Aged | Bone Marrow Neoplasms - drug therapy | Neoplasm Staging | Central Nervous System Neoplasms - drug therapy | Methylprednisolone - administration & dosage | Chemotherapy | Leukemia | Lymphomas | Adults | Epidemiology | Biometry | Cancer | Survival analysis | Biomedical research | Dehydrogenases | Medical prognosis | Clinical trials
Journal Article
Lancet, The, ISSN 0140-6736, 2011, Volume 378, Issue 9806, pp. 1858 - 1867
Summary Background The outcome of diffuse large B-cell lymphoma has been substantially improved by the addition of the anti-CD20 monoclonal antibody rituximab... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | MULTICENTER | RESPONSE CRITERIA | AGGRESSIVE LYMPHOMAS | POOR-PROGNOSIS | NON-HODGKINS-LYMPHOMA | REGIMEN | YOUNG-PATIENTS | ELDERLY-PATIENTS | DES-LYMPHOMES | TRANSPLANTATION | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cyclophosphamide - adverse effects | Dose-Response Relationship, Drug | Young Adult | Vindesine - adverse effects | Adult | Female | Prednisolone | Doxorubicin - administration & dosage | Severity of Illness Index | Prednisone - administration & dosage | Lymphoma, Large B-Cell, Diffuse - drug therapy | Prednisone - adverse effects | Drug Administration Schedule | Risk Assessment | Rituximab | Treatment Outcome | Bleomycin - administration & dosage | Bleomycin - adverse effects | Vincristine | Lymphoma, Large B-Cell, Diffuse - mortality | Disease-Free Survival | Lymphoma, Large B-Cell, Diffuse - diagnosis | Maximum Tolerated Dose | Adolescent | Survival Analysis | Vindesine - administration & dosage | Doxorubicin - adverse effects | Chemotherapy | Physiological aspects | Lymphomas | B cells | Drug therapy | Methods | Cancer | Dehydrogenases | Toxicity | Population studies | Doxorubicin | Hepatitis | Randomization | Bleomycin | Motivation | Drug dosages | Neutropenia | Cell survival | Hematology | Prednisone | Survival | Patients | Lymphoma | Cyclophosphamide | Lymphocytes B | Monoclonal antibodies | CD20 antigen | Tumors | B-cell lymphoma | Clinical trials | Public speaking | Grants | Clinical medicine | Side effects | lymphoma | survival | International standardization | chemotherapy
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 6, pp. 525 - 533
Journal Article
Journal Article
British Journal of Haematology, ISSN 0007-1048, 10/2018, Volume 183, Issue 1, pp. 76 - 86
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 2014, Volume 32, Issue 10, pp. 1066 - 1073
Journal Article
Haematologica, ISSN 0390-6078, 08/2011, Volume 96, Issue 8, pp. 1136 - 1143
Journal Article
Journal Article
American Journal of Hematology, ISSN 0361-8609, 02/2016, Volume 91, Issue 2, pp. 179 - 184
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 11/2015, Volume 33, Issue 33, pp. 3930 - 3937
Journal Article
by Cerhan, James R and Berndt, Sonja I and Vijai, Joseph and Ghesquières, Hervé and McKay, James and Wang, Sophia S and Wang, Zhaoming and Yeager, Meredith and Conde, Lucia and De Bakker, Paul I W and Nieters, Alexana and Cox, David and Burdett, Laurie and Monnereau, Alain and Flowers, Christopher R and De Roos, Anneclaire J and Brooks-Wilson, Angela R and Lan, Qing and Severi, Gianluca and Melbye, Mads and Gu, Jian and Jackson, Rebecca D and Kane, Eleanor and Teras, Lauren R and Purdue, Mark P and Vajdic, Claire M and Spinelli, John J and Giles, Graham G and Albanes, Demetrius and Kelly, Rachel S and Zucca, Mariagrazia and Bertrand, Kimberly A and Zeleniuch-Jacquotte, Anne and Lawrence, Charles and Hutchinson, Amy and Zhi, Degui and Habermann, Thomas M and Link, Brian K and Novak, Anne J and Dogan, Ahmet and Asmann, Yan W and Liebow, Mark and Thompson, Carrie A and Ansell, Stephen M and Witzig, Thomas E and Weiner, George J and Veron, Amelie S and Zelenika, Diana and Tilly, Hervé and Haioun, Corinne and Molina, Thierry Jo and Hjalgrim, Henrik and Glimelius, Bengt and Adami, Hans Olov and Bracci, Paige M and Riby, Jacques and Smith, Martyn T and Holly, Elizabeth A and Cozen, Wendy and Hartge, Patricia and Morton, Lindsay M and Severson, Richard K and Tinker, Lesley F and North, Kari E and Becker, Nikolaus and Benavente, Yolanda and Boffetta, Paolo and Brennan, Paul and Foretova, Lenka and Maynadie, Marc and Staines, Anthony and Lightfoot, Tracy and Crouch, Simon and Smith, Alex and Roman, Eve and Diver, W. Ryan and Offit, Kenneth and Zelenetz, Anew and Klein, Robert J and Villano, Danylo J and Zheng, Tongzhang and Zhang, Yawei and Holford, Theodore R and Kricker, Anne and Turner, Jenny and Southey, Melissa C and Clavel, Jacqueline and Virtamo, Jarmo and Weinstein, Stephanie and Riboli, Elio and Vineis, Paolo and Kaaks, Rudolph and Trichopoulos, Dimitrios and Vermeulen, Roel C H and Boeing, Heiner and Tjonneland, Anne and Angelucci, Emanuele and Di Lollo, Simonetta and Rais, Marco and Birmann, Brenda M and ... and Medicinska fakulteten and Medicinska och farmaceutiska vetenskapsområdet and Institutionen för radiologi, onkologi och strålningsvetenskap and Uppsala universitet and Enheten för onkologi
Nature Genetics, ISSN 1061-4036, 01/2014, Volume 46, Issue 11, pp. 1233 - 1238
Journal Article